| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519252 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(6 months ago) | |
| US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(6 months ago) | |
| US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(6 months ago) | |
| US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(6 months ago) | |
| US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(6 months ago) | |
| US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2024
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364260 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) | |
Injectafer is owned by Am Regent.
Injectafer contains Ferric Carboxymaltose.
Injectafer has a total of 11 drug patents out of which 6 drug patents have expired.
Expired drug patents of Injectafer are:
- US10519252
- US11590097
- US11291645
- US11123321
- US9376505
- US7612109
Injectafer was authorised for market use on 28 April, 2021.
Injectafer is available in solution;intravenous dosage forms.
Injectafer can be used as method of treating iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose, method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less, method to treat iron deficiency in adults weighing at least 40 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provide at least about 0.6 g of elemental iron, a method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide 500 to 750 mg of elemental iron, method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less, method of treating ida in adult patients weighing at least 46.7 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provide at least 0.7 g of elemental iron in 15 minutes, method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron.
The generics of Injectafer are possible to be released after 15 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-915) | May 31, 2026 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Strength(NS) | Apr 28, 2024 |
| New Product(NP) | Jul 25, 2016 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method to treat iron deficiency in adults weighing at least 40 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provi...
Dosage: SOLUTION;INTRAVENOUS
INJECTAFER family patents
